艾美赛珠单抗改变儿童A型血友病管理格局
本文基于2020年国际血栓与止血学会虚拟会议的最新报告,阐述艾美赛珠单抗如何重塑儿童A型血友病的治疗策略。文章指出传统凝血因子替代治疗受限于资源可及性和抑制物形成,而艾美赛珠单抗已在多国上市,提供了新的管理路径和临床适用算法。
要点
- 艾美赛珠单抗正在改变儿童A型血友病的治疗方式。
- 传统因子替代治疗受限于资源可及性和抑制物形成。
- 文章提供了艾美赛珠单抗时代的临床适用算法。
核心结论
- 艾美赛珠单抗正在重塑儿童A型血友病的治疗格局。
研究设计与样本
- 本文为论坛文章,基于2020年国际血栓与止血学会虚拟会议的最新报告。
主要发现
- 有效预防治疗可使年轻男性成年时关节功能良好且少有其他后遗症。
- 资源丰富国家中因子浓缩物供应充足,但治疗负担和抑制物形成限制理想结局。
- 全球多数地区因子浓缩物过于昂贵而无法成为治疗选择。
- 艾美赛珠单抗已在全球多个国家上市。
临床怎么用
- 文章提出了在艾美赛珠单抗新时代治疗儿童A型血友病的临床适用算法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The key to having a good quality of life for an adult with hemophilia rests largely on how he or she was managed as children. With effective prophylaxis, young men can begin their adult life with excellent joint function and few, if any, other sequelae from their disease. Unfortunately, this outcome is not always (nor often) attained because of the limitations of the mainstay of treatment, which is factor replacement therapy. In resource-rich countries with an adequate supply of factor concentrates, the treatment burden and formation of inhibitors limit the potential for an ideal outcome, whereas in much of the world, factor concentrates are too expensive to even be an option. The novel agent, emicizumab, which has become available in numerous countries around the world, is reshaping how one approaches the treatment of children with hemophilia A. This Forum Article, based on a State-of-the-Art lecture given at the 2020 International Society on Thrombosis and Haemostasis Virtual Meeting, presents an approach including clinically applicable algorithms for treating children with hemophilia A in the new era with emicizumab.
引用
- Young G. Management of children with hemophilia A: How emicizumab has changed the landscape. J Thromb Haemost. 2021. PMID: 33872458. doi:10.1111/jth.15342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。